Education
About Us
Working with TipRanks
Follow Us
Climb Bio, Inc. (CLYM)
NASDAQ:CLYM
CLYM Stock Chart & Stats
$7.28
-$0.15(-7.18%)
At close: 4:00 PM EST
$7.28
-$0.15(-7.18%)
Day’s Range― - ―
52-Week Range$1.05 - $7.59
Previous CloseN/A
Volume51.97K
Average Volume (3M)626.28K
Market Cap
$483.43M
Enterprise Value$471.16M
Total Cash (Recent Filing)$86.90M
Total Debt (Recent Filing)$580.00K
Price to Earnings (P/E)―
Beta1.19
Next Earnings
May 19, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding68,184,430
10 Day Avg. Volume711,545
30 Day Avg. Volume626,276
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-12.40K
Enterprise Value/Ebitda-8.50
Forecast
1Y Price Target
$13.00Price Target Upside78.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Mechanism ValidationPositive Phase 3 results in primary membranous nephropathy validate B-cell depletion as an effective approach, supporting budoprutug's CD19-targeting mechanism and increasing confidence in its therapeutic rationale.
Near-term Clinical CatalystsMultiple major clinical milestones expected in 2026, including budoprutug Phase II results and initial CLYM116 data, create a steady catalyst schedule that could drive share upside if outcomes are positive.
Pipeline BreadthEvaluation of budoprutug across primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus creates multiple independent opportunities to generate clinical proof and commercial value from a single product candidate.
Bears Say
Clinical Development RiskClinical success for budoprutug remains unproven and hinges on ongoing mid-stage trials, exposing the program to material development and execution risk.
Enrollment RiskA slow pace of patient enrollment could reduce the number of evaluable patients in upcoming updates, increasing uncertainty about the completeness and interpretability of the results.
Limited Early ReadoutThe initial Phase II update is likely to include mainly a low-dose cohort and pharmacodynamic markers rather than robust clinical remission data, limiting its ability to demonstrate clear efficacy.
Climb Bio News
CLYM FAQ
What was Climb Bio, Inc.’s price range in the past 12 months?
Climb Bio, Inc. lowest stock price was $1.05 and its highest was $7.59 in the past 12 months.
What is Climb Bio, Inc.’s market cap?
Climb Bio, Inc.’s market cap is $483.43M.
When is Climb Bio, Inc.’s upcoming earnings report date?
Climb Bio, Inc.’s upcoming earnings report date is May 19, 2026 which is in 75 days.
How were Climb Bio, Inc.’s earnings last quarter?
Climb Bio, Inc. released its earnings results on Mar 05, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.197 by -$0.063.
Is Climb Bio, Inc. overvalued?
According to Wall Street analysts Climb Bio, Inc.’s price is currently Undervalued.
Does Climb Bio, Inc. pay dividends?
Climb Bio, Inc. does not currently pay dividends.
What is Climb Bio, Inc.’s EPS estimate?
Climb Bio, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Climb Bio, Inc. have?
Climb Bio, Inc. has 68,184,430 shares outstanding.
What happened to Climb Bio, Inc.’s price movement after its last earnings report?
Climb Bio, Inc. reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.197. Following the earnings report the stock price went up 1.563%.
Which hedge fund is a major shareholder of Climb Bio, Inc.?
Currently, no hedge funds are holding shares in CLYM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Climb Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (78.52% Upside)
$13.00 (78.52% Upside)
Blogger Sentiment
Bullish
CLYM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 19.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $779.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
427.53%
12-Months-Change
Fundamentals
Return on Equity
-25.65%
Trailing 12-Months
Asset Growth
-17.95%
Trailing 12-Months
Company Description
Climb Bio, Inc.
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.
CLYM Stock 12 Month Forecast
Average Price Target
$13.00
▲(78.52% Upside)
Technical Analysis
Agenus
―
TuHURA Biosciences
―
Ovid Therapeutics
―
Cognition Therapeutics
―
Tevogen Bio Holdings
―
Ownership Overview
17.12% Insiders
2.82% Mutual Funds
3.85% Other Institutional Investors
74.42% Public Companies and
Individual Investors